Here, we choose to discuss only a few critical instances by which aberrant LLPS can inhibit antitumor signaling pathways, leading to tumorigenesis. However, this is just the tip of the iceberg, and a number of other mechanisms and systems likely exist. Nevertheless, there are currently some promising therapeutic strategies that can be applied to inhibit tumorigenic biomolecular condensate formation, such as normalizing the phase-separating proteins' concentrations through drug targets via protein posttranslational modification enzymes or partitioning of small molecules which inhibit phase separation directly into condensates. More studies on animal models are required to explore and expand our scope of potential anticancer drugs and medications that can moderate and control aberrant cancer-related LLPS, potentially preventing cancers early on before malignancy.